

Hill, M.
09/641528

09/641528

FILE 'REGISTRY' ENTERED AT 09:33:32 ON 10 FEB 2003
L1 3 S ATLERTEVY/SQSP

L1 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2003 ACS
RN 485119-52-6 REGISTRY
CN GenBank AAA46973 (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank AAA46973 (Translated from: GenBank M38198)
CI MAN
SQL 158

SEQ 1 MARFDDPKQP PYKLPLDLCTE LNTSLQDVSN ACVYCKATLE RTEVYQFAFK
=====
51 DLCIVYRDCI AYAACHKCID FYSRIRELRY YSNSVYGETL EKITNTELYN
101 LLIRCLRCQK PLNPAEKARH LKDKRRFHSI AGQYRGQCNT CCDQARQERL
151 RRRRETQV
HITS AT: 37-45

L1 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2003 ACS
RN 459720-81-1 REGISTRY
CN GenBank AJ242956-derived protein GI 5042224 (9CI) (CA INDEX NAME)
CI MAN
SQL 158

SEQ 1 MARFDDPTQR PYKLPLDLCTE LNTSLQDVSI ACVYCKATLE RTEVYQFAFK
=====
51 DLFIVYRDCI AYAACHKCID FYSRIRELRY YSNSVYGETL EKITNTELYN
101 LLIRCLRCQK PLNPAEKRRH LKDKRRFHSI AGQYRGQCNT CCDQARQERL
151 RRRRETQV
HITS AT: 37-45

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L1 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2003 ACS
RN 312330-93-1 REGISTRY
CN Protein E6 (human cervical carcinoma cell IC4 IC4 gene HPV45E6
(human papillomavirus 45 gene E6)) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 50: PN: WO0141799 PAGE: 25 claimed sequence
CN Protein E6 (human papillomavirus 45)
CI MAN
SQL 158

SEQ 1 MARFDDPTQR PYKLPLDLCTE LNTSLQDVSI ACVYCKATLE RTEVYQFAFK
=====
51 DLFIVYRDCI AYAACHKCID FYSRIRELRY YSNSVYGETL EKITNTELYN
101 LLIRCLRCQK PLNPAEKRRH LKDKRRFHSI AGQYRGQCNT CCDQARQERL
151 RRRRETQV
HITS AT: 37-45

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 135:45179

REFERENCE 2: 134:25996

FILE 'HCAPLUS' ENTERED AT 09:34:14 ON 10 FEB 2003
L2 2 S L1

09/641528

L2 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:434895 HCAPLUS

DOCUMENT NUMBER: 135:45179

TITLE: Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions

INVENTOR(S): Sette, Alessandro; Sidney, John; Southwood, Scott; Chesnut, Robert; Celis, Esteban; Grey, Howard M. *Jamz*

PATENT ASSIGNEE(S): Epimmune Inc., USA

SOURCE: PCT Int. Appl., 756 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001041799	A1	20010614	WO 2000-US33549	20001211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1246644	A1	20021009	EP 2000-986316	20001211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:				
US 1999-172705P P 19991210				
US 2000-641528 A 20000815				
WO 2000-US33549 W 20001211				
AB This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prep. human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compns. and methods of use in the prevention and treatment of HPV infection. The disclosed human papillomavirus protein epitopes include HLA-A1, HLA-A2, HLA-A3, HLA-A24, HLA-B7, HLA-B27, HLA-B58, HLA-B62 and HLA-DR supermotifs; and HLA-A1, HLA-A2, HLA-A3, HLA-A24, HLA-A11, HLA-DR3a and HLA-DR3b motifs. These supermotifs and motifs are derived from E1, E2, E5, E6, E7, L1 and L2 proteins of HPV16, HPV18, HPV31, HPV33, HPV45, HPV56, HPV6A, HPV6B, and HPV11.				
IT 312330-93-1				
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)				
(amino acid sequence; epitope-based vaccines for inducing cellular immune responses to human papillomavirus)				
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

09/641528

L2 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:557272 HCAPLUS

DOCUMENT NUMBER: 134:25996

TITLE: Distinct patterns of alteration of myc genes associated with integration of human papillomavirus type 16 or type 45 DNA in two genital tumours

AUTHOR(S): Sastre-Garau, Xavier; Favre, Michel; Couturier, Jerome; Orth, Gerard

CORPORATE SOURCE: Unite Mixte Institut Pasteur/INSERM (U.190), Institut Pasteur, Paris, F-75724, Fr.

SOURCE: ~~Journal of General Virology (2000), 81(8), 1983-1993~~

CODEN: JGVIAY; ISSN: 0022-1317

PUBLISHER: Society for General Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We previously described two genital carcinomas (IC2, IC4) contg. human papillomavirus type 16 (HPV-16)- or HPV-18-related sequences integrated in chromosomal bands contg. the c-myc (8q24) or N-myc (2p24) gene, resp. The c-myc gene was rearranged and amplified in IC2 cells without evidence of overexpression. The N-myc gene was amplified and highly transcribed in IC4 cells. Here, the sequence of an 8039 bp IC4 DNA fragment contg. the integrated viral sequences and the cellular junctions is reported. A 3948 bp segment of the genome of HPV-45 encompassing the upstream regulatory region and the E6 and E7 ORFs was integrated into the untranslated part of N-myc exon 3, upstream of the N-myc polyadenylation signal. Both N-myc and HPV-45 sequences were amplified 10- to 20-fold. The 3' ends of the major N-myc transcript were mapped upstream of the 5' junction. A minor N-myc/HPV-45 fusion transcript was also identified, as well as two abundant transcripts from the HPV-45 E6-E7 region. Large amts. of N-myc protein were detected in IC4 cells. A major alteration of c-myc sequences in IC2 cells involved the insertion of a non-coding sequence into the second intron and their co-amplification with the third exon, without any evidence for the integration of HPV-16 sequences within or close to the gene. Different patterns of myc gene alterations may thus be assocd. with integration of HPV DNA in genital tumors, including the activation of the protooncogene via a mechanism of insertional mutagenesis and/or gene amplification.

IT 312330-93-1

RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)

(amino acid sequence; distinct patterns of alteration of myc genes assocd. with integration of human papillomavirus type 16 or type 45 DNA in two genital tumors)

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

FILE 'HOME' ENTERED AT 09:34:25 ON 10 FEB 2003